Advertisement

Topics

Companies Related to "Therapeutic Tumor-Selective Donor Lymphocytes and Aldesleukin in Treating Patients With Malignant Glioma" [Most Relevant Company Matches] RSS

09:12 EST 20th November 2018 | BioPortfolio

Here are the most relevant search results for "Therapeutic Tumor-Selective Donor Lymphocytes and Aldesleukin in Treating Patients With Malignant Glioma" found in our extensive corporate database of over 50,000 company records.

Showing "Therapeutic Tumor Selective Donor Lymphocytes Aldesleukin Treating Patients" Companies 1–25 of 5,700+

Extremely Relevant

Keel Pharmaceuticals, Inc.

Keel Pharmaceuticals, Inc. is a private biopharmaceutical company that is developing new therapies to treat type 1 diabetes and other autoimmune diseases. Keels technology is based on the identification of specific protein processing and signalling defects present in the autoreactive white blood cells (lymphocytes) that cause autoimmune diseases. The identification of these defects has yielded a...


Relevant

Donor Dialogue

Donor Dialogue, a division of Dialogue Marketing, provides products and services to help blood centers be more efficient, productive and profitable. Donor Dialogue’s Customer Relationship Management (CRM) software, targeted marketing tools and data analysis services support blood center operations to drive blood donor recruitments. With its highly tra...

Genetronics Biomedical

Genetronics' most advanced effort involves treating those with head and neck cancer, a particularly devastating cancer that can severely limit the ability of these patients to see, taste, hear, talk, breathe, or swallow. Genetronics received approval from the U.S. Food and Drug Administration and initiated Phase II multi-center clinical trials at nine sites in the U.S. The trials test the effectiv...


4SC AG

4SC AG (ISIN DE0005753818) is a drug discovery and development company focused on autoimmune and cancer indications. Vidofludimus (4SC-101), a small molecule, is currently in a Phase IIb study in rheumatoid arthritis and a Phase IIa exploratory study in inflammatory bowel disease. The company's lead oncology compound, resminostat (4SC-201), a pan histone d...

Pharmablood

PharmaBlood performs R&D of personalized medical treatment methods using as therapeutic agents autologous blood derivative compositions in cancer patients.PharmaBlood is a trademark of Telemedical Organization Inc used to identify the activity of the company in the field of research and development of blood derivatives as medical therapeuticals.Telemedical Organization Inc is an American company w...

Paragonix Technologies Inc.

Based in Cambridge, Massachusetts and founded in 2010, Paragonix Technologies Inc., is a privately held medical device company innovating the Paragonix Sherpa™ Cardiac Transport System, a novel, single-use organ preservation device to improve donor organ quality and extend donor organ preservation times. Paragonix Sherpa™ combines innovative oxyg...

AdnaGen AG

AdnaGen's diagnostics detect circulating tumor cells in tumor patients. Because tumor cells survive only hours in the bloodstream, there must be an active source, e.g. a relapse or a metastasis. Therefore, the presence of circulating tumor cells is an unfavorable indicator for the progress of the tumor disease. AdnaGen's proprietary 'combination-of-combinations-principle' allows the reliable and v...

Intezyne

Intezyne is dedicated to treating cancer better by offering a new solution to oncologists, who must balance the anti-tumor activity of best-in-class chemotherapeutics with their severe toxicities. Drawing from their expertise in polymer chemistry, the Company’s founders created the IVECT Method to limit chemotherapeutics’ anti-tumor activity to w...

RTI Donor Services, Inc.

RTI Donor Services, Inc. (RTI Donor Services) is a nonprofit tissue recovery agency dedicated to serving donor families and working in collaboration with the donation community and healthcare facilities in perpetuating the gift of tissue donation. RTI Donor Services is accredited by the American Association of Tissue Banks and affiliated with RTI Surgical,...

Paragonix Technologies, Inc.

Based in Cambridge, Massachusetts and founded in 2010, Paragonix Technologies, Inc., is a privately held medical device company innovating the Paragonix Sherpa™ Cardiac Transport Systems, which are novel, single-use organ preservation devices to improve donor organ quality and extend donor organ preservation times. Paragonix Sherpa™ combines inno...

Lion Biotechnologies, Inc.

Lion Biotechnologies, Inc., formerly Genesis Biopharma, Inc., is engaged in the development of T-cells and engineered T-cells for the treatment of various cancers. The company's lead product candidate is a ready-to-infuse autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TILs) for the treatment of patients with Stage IV metastatic melanom...

Prolexys Pharmaceuticals, Inc.

Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company’s therapeutic focus is on cancer and cardiovascular indications where Prolexys has identified novel, druggable therapeutic targets. Small molecules that act at these targets have been identified and tested in cell and animal models of diseas...

Affigen

Affigen (www.affigen.com) develops tumor-identifying therapeutics that target cell lineage-specific tumor proteins in certain incurable cancers. The Company's growing team houses deep expertise in immuno-oncology, mass-personalized biomolecular engineering and complex therapeutic development, and is working to deliver a new class of therapeutics that ...

AC Vaccine technology

The AC Vaccine technology is a therapuetic treatment based on the concept of haptenization. This idea has a long history, beginning with the work of the immunologist and Nobel laureate Karl Landsteiner in the 1920’s. He and other scientists showed in animal models that attaching a small chemical (a hapten) to a protein allowed that protein to be recognized by the immune system even if the anim...

WindMIL Therapeutics

When it comes to cell therapy – cell source matters. At WindMIL, we are harnessing the power of bone marrow derived lymphocytes (MILs™) to develop ground-breaking immunotherapies to treat cancer patients. The bone marrow is a natural reservoir of T cells with unique advantages including inherent tumor-specificity. We have perfected an efficient and ...

The National Marrow Donor Program

The National Marrow Donor Program (NMDP) is the global leader in providing marrow and umbilical cord blood transplants to patients with leukemia, lymphoma and other diseases. The nonprofit organization matches patients with donors, educates health care professionals and conducts research so more lives can be saved. The NMDP also operates Be The Match®, ...

Alpha Therapeutic Corporation

Alpha Therapeutic helps set industry standards with comprehensive donor screening and innovative use of viral inactivation techniques .The company was founded in 1948 in Los Angeles as Courtland Laboratories. In 1978, it was incorporated in California as Alpha Therapeutic Corporation. Alpha's parent company, Mitsubishi Pharma Corporation, is traded on the Japanese Stock Exchange.

APO-T B.V. and LinXis B.V.

APO-T is a biopharmaceutical company focused on the development and commercialization of proprietary biotherapeutics for oncology. APO-T has developed fully-human antibodies and antibody fragments that target any tumor cell that expresses a MAGE-A peptide in the context of MHC-1. Many different kinds of tumors expose this MAGE-MHC-1 peptide complex. They a...

Replicon Technologies Incorporated

Replicon Technologies, Inc. (RTI) is an emerging biotechnology company focused on the use of replicons, non-replicating RNA viral particles, for the treatment of patients with cancer. RTI is founded on research and development performed at the University of Alabama at Birmingham (UAB), and supported by competitive grants from the National Institutes of Health, the Department of Defense, and SBIR ...

NeoRX Corporation

NeoRx Corporation develops innovative therapeutic biopharmaceuticals primarily for the treatment of cancer, cardiovascular, and inflammatory diseases. As part of its cancer treatment program, NeoRx is currently conducting a Phase I trial of its Skeletal Targeted Radiation ("STR") product combined with chemotherapy in patients with multiple myeloma. NeoRx is also developing a proprietary PRETARGET-...

Selective Insurance Group, Inc.

Selective Insurance Group, Inc. is a holding company for seven property and casualty insurance companies rated "A+" (Superior) by A.M. Best. Through independent agents, the insurance companies offer primary and alternative market insurance for commercial and personal risks, and flood insurance underwritten by the National Flood Insurance Program. Other subsidiaries of the company provide human res...

Direct Therapeutics, Inc.

Direct Therapeutics, Inc. is a development-stage pharmaceutical company using its patented Solvent-Facilitated Perfusion technology to create new drugs for the localized and regional treatment of solid-tumor cancers. Our products are designed for direct injection to target tissue with minimal invasion of healthy tissue. They contain active ingredients in organic solvent vehicles that facilitate th...

OncoPep

OncoPep is developing targeted immunotherapeutics to prevent the progression of cancer, prolong survival and restore the quality of life of patients. OncoPep’s lead program is a multi-peptide therapeutic vaccine for use in treating smoldering multiple myeloma. www.oncopep.com

OncoPep, Inc.

OncoPep is developing targeted immunotherapeutics to prevent the progression of cancer, prolong survival and restore the quality of life of patients. OncoPep’s lead program is a multi-peptide therapeutic vaccine for use in treating smoldering multiple myeloma. www.oncopep.com

Calistoga Pharmaceuticals, Inc.

Calistoga Pharmaceuticals is dedicated to developing targeted therapy to improve the health of patients with cancer and inflammatory diseases. Calistoga Pharmaceuticals has a portfolio of proprietary compounds selectively targeting isoforms of the PI3K pathway. The Company’s most advanced compound, CAL-101, a selective PI3K delta inhibitor, is under c...


More From BioPortfolio on "Therapeutic Tumor-Selective Donor Lymphocytes and Aldesleukin in Treating Patients With Malignant Glioma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks